{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:01:28Z","timestamp":1787907688158,"version":"build-2784847793"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["314486\/2023-2"],"award-info":[{"award-number":["314486\/2023-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310905\/2020-6"],"award-info":[{"award-number":["310905\/2020-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009730","name":"UFOP","doi-asserted-by":"publisher","award":["23109.009436\/2023\\u201356"],"award-info":[{"award-number":["23109.009436\/2023\\u201356"]}],"id":[{"id":"10.13039\/501100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009730","name":"UFOP","doi-asserted-by":"publisher","award":["23109.016819\/2023-81"],"award-info":[{"award-number":["23109.016819\/2023-81"]}],"id":[{"id":"10.13039\/501100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"publisher","award":["APQ-03555-22"],"award-info":[{"award-number":["APQ-03555-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejphar.2024.176907","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T02:41:07Z","timestamp":1723776067000},"page":"176907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases"],"prefix":"10.1016","volume":"981","author":[{"given":"L\u00edvia da Cunha","family":"Agostini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0970-291X","authenticated-orcid":false,"given":"Nayara Nascimento Toledo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa de Almeida","family":"Belo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-3525","authenticated-orcid":false,"given":"Marcelo Rizzatti","family":"Luizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Alves","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9751-3379","authenticated-orcid":false,"given":"Glenda Nicioli","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.21037\/cdt-20-358","article-title":"Medical management of pediatric heart failure","volume":"11","author":"Ahmed","year":"2021","journal-title":"Cardiovasc. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","article-title":"A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril","volume":"8","author":"Ancion","year":"2019","journal-title":"Cardiology and Therapy"},{"issue":"12","key":"10.1016\/j.ejphar.2024.176907_bib3","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1017\/S104795112100130X","article-title":"Racial and ethnic differences in response to treatment for Marfan syndrome","volume":"31","author":"Ayers","year":"2021","journal-title":"Cardiol. Young"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/01.HYP.28.6.1081","article-title":"Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals","volume":"28","author":"Benetos","year":"1996","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ajh.2008.341","article-title":"G-Protein-Coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among african Americans: sex-specificity and interactions","volume":"22","author":"Bhatnagar","year":"2009","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/ajh.2009.38","article-title":"Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics","volume":"22","author":"Bozkurt","year":"2009","journal-title":"Am. J. Hypertens."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2003.12.033","article-title":"Effects of ACE gene insertion\/deletion polymorphism on response to spironolactone in patients with chronic heart failure","volume":"116","author":"Cicoira","year":"2004","journal-title":"Am. J. Med."},{"issue":"December","key":"10.1016\/j.ejphar.2024.176907_bib8","first-page":"1","article-title":"Racial and sex differences in the response to first-line antihypertensive therapy","volume":"7","author":"Clemmer","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1159\/000510433","article-title":"Genotype-guided hydralazine therapy","volume":"51","author":"Collins","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrneph.2015.176","article-title":"Hypertension pharmacogenomics: in search of personalized treatment approaches","volume":"12","author":"Cooper-DeHoff","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s11033-024-09437-1","article-title":"Single nucleotide polymorphism (SNP) rs4291 of the angiotensin-converting enzyme (ACE) gene is associated with the response to losartan treatment in hypertensive patients","volume":"51","author":"da C Agostini","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"7","key":"10.1016\/j.ejphar.2024.176907_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/children5070088","article-title":"Current state of pediatric heart failure","volume":"5","author":"Das","year":"2018","journal-title":"Children"},{"issue":"7","key":"10.1016\/j.ejphar.2024.176907_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2217\/pgs-2018-0004","article-title":"A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure","volume":"19","author":"de Denus","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/ijmr.IJMR_1209_17","article-title":"Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia","volume":"150","author":"de Oliveira","year":"2019","journal-title":"Indian J. Med. Res."},{"issue":"7\u20138","key":"10.1016\/j.ejphar.2024.176907_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1345\/aph.1K657","article-title":"Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan","volume":"42","author":"Denus","year":"2008","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40256-016-0185-0","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on prothrombotic processes and myocardial infarction risk","volume":"16","author":"D\u00e9zsi","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"9","key":"10.1016\/j.ejphar.2024.176907_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/jhh.2015.121","article-title":"The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study","volume":"30","author":"Do","year":"2016","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2024.176907_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","author":"Duarte","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.34067\/KID.0005362021","article-title":"Pharmacogenomics of hypertension in CKD: the CKD-PGX study","volume":"3","author":"Eadon","year":"2022","journal-title":"Kidney360"},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/jhh.2014.76","article-title":"An update on the pharmacogenetics of treating hypertension","volume":"29","author":"Fontana","year":"2015","journal-title":"J. Hum. Hypertens."},{"issue":"13","key":"10.1016\/j.ejphar.2024.176907_bib22","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2217\/pgs.14.119","article-title":"Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the sophia study","volume":"15","author":"Frau","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12291-019-00860-x","article-title":"Genetic polymorphism of angiotensin II type 1 receptors and their effect on the clinical outcome of captopril treatment in arab Iraqi patients with acute coronary syndrome (mid euphrates)","volume":"36","author":"Ghafil","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib24","article-title":"Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese","volume":"20","author":"Gong","year":"2019","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12041-018-1053-2","article-title":"Association of polymorphisms of CYP11B2 gene \u2013344C\/T and ACE gene I\/D with antihypertensive response to angiotensin receptor blockers in Chinese with hypertension","volume":"98","author":"Gong","year":"2019","journal-title":"J. Genet."},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/1440-1681.12525","article-title":"The prevalence of unique <scp>SNP<\/scp> s in the renin\u2010angiotensin system highlights the need for pharmacogenetics in Indigenous Australians","volume":"43","author":"Grimson","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/pgs-2016-0184","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population","volume":"18","author":"Hallberg","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.HYP.0000088322.85804.96","article-title":"The ACE gene I\/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition","volume":"42","author":"Harrap","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/03014460400027458","article-title":"A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril","volume":"32","author":"He","year":"2005","journal-title":"Ann. Hum. Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2024.176907_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.21037\/atm.2020.03.176","article-title":"TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension","volume":"8","author":"He","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/1470320314538878","article-title":"Association of insertion\/deletion polymorphism of angiotensin-converting enzyme gene among Malay male hypertensive subjects in response to ACE inhibitors","volume":"16","author":"Heidari","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"key":"10.1016\/j.ejphar.2024.176907_bib32","doi-asserted-by":"crossref","DOI":"10.3892\/br.2017.1009","article-title":"Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population","author":"Herrera-Gonz\u00e1lez","year":"2017","journal-title":"Biomedical Reports"},{"key":"10.1016\/j.ejphar.2024.176907_bib33","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","author":"Hicks","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001521","article-title":"Pharmacogenomics of hypertension: a genome\u2010wide, placebo\u2010controlled cross\u2010over study, using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.ejphar.2024.176907_bib35","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/10641963.2018.1529782","article-title":"Serum concentration of renin-angiotensin system components in association with ACE I\/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy","volume":"41","author":"Hristova","year":"2019","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.ejphar.2024.176907_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105835","article-title":"Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management","volume":"172","author":"Hundemer","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2024.176907_bib37","first-page":"1","article-title":"Pharmacogenetic study of ACE, AGT, CYP11B1, CYP11B2 and eNOS gene variants in hypertensive patients from Faisalabad, Pakistan","author":"Hussain","year":"2020","journal-title":"JPMA (J. Pak. Med. Assoc.)"},{"issue":"12","key":"10.1016\/j.ejphar.2024.176907_bib38","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3390\/genes13122225","article-title":"The influence of structural variants of the CES1 gene on the pharmacokinetics of enalapril, presumably due to linkage disequilibrium with the intronic rs2244613","volume":"13","author":"Ikonnikova","year":"2022","journal-title":"Genes"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib39","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1097\/HJH.0b013e32833c7a4d","article-title":"Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study","volume":"28","author":"Irvin","year":"2010","journal-title":"J. Hypertens."},{"issue":"9","key":"10.1016\/j.ejphar.2024.176907_bib40","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/01.STR.0000027274.03779.F3","article-title":"Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II at 1 antagonist","volume":"33","author":"Ito","year":"2002","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1523-1755.1998.00847.x","article-title":"Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy","volume":"53","author":"Jacobsen","year":"1998","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/HJH.0b013e32834494f6","article-title":"Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan","volume":"29","author":"Jiang","year":"2011","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10741-018-09765-y","article-title":"Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review","volume":"24","author":"Johnson","year":"2019","journal-title":"Heart Fail. Rev."},{"issue":"12","key":"10.1016\/j.ejphar.2024.176907_bib44","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s12272-021-01363-1","article-title":"Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients","volume":"44","author":"Jung","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2350-10-50","article-title":"ACE (I\/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation","volume":"10","author":"Kitsios","year":"2009","journal-title":"BMC Med. Genet."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/1874192401509010118","article-title":"Angiotensinogen (AGT) M235T, AGT T174M and angiotensin-1- converting enzyme (ACE) I\/D gene polymorphisms in essential hypertension: effects on ramipril efficacy","volume":"9","author":"Kolovou","year":"2015","journal-title":"Open Cardiovasc. Med. J."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib47","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/00004872-200110000-00012","article-title":"Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients","volume":"19","author":"Kurland","year":"2001","journal-title":"J. Hypertens."},{"issue":"11","key":"10.1016\/j.ejphar.2024.176907_bib48","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/meta.2001.27212","article-title":"Angiotensin-converting enzyme gene insertion\/deletion, not bradykinin B2 receptor -58T\/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non[ndash ]insulin-dependent diabetes mellitu","volume":"50","author":"Lee","year":"2001","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/FPC.0b013e32835a0ffa","article-title":"Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease","volume":"23","author":"Lee","year":"2013","journal-title":"Pharmacogenetics Genom."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3349\/ymj.2022.63.4.342","article-title":"Genetic variants associated with adverse events after angiotensin-converting enzyme inhibitor use: replication after GWAS-based discovery","volume":"63","author":"Lee","year":"2022","journal-title":"Yonsei Med. J."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajh\/hpab108","article-title":"Renin angiotensin blockers and cardiac protection: from basics to clinical trials","volume":"35","author":"L\u00e9vy","year":"2022","journal-title":"Am. J. Hypertens."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10641963.2010.531838","article-title":"Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in han Chinese hypertensive patients","volume":"33","author":"Li","year":"2011","journal-title":"Clin. Exp. Hypertens."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037396","article-title":"Angiotensin-converting enzyme (ACE) gene insertion\/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12863-021-00999-8","article-title":"Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China","volume":"22","author":"Li","year":"2021","journal-title":"BMC Genomic Data"},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1089\/gtmb.2018.0232","article-title":"The effect of angiotensin-converting enzyme gene polymorphisms on the clinical efficacy of perindopril prescribed for acute myocardial infarction in Chinese han patients","volume":"23","author":"Lin","year":"2019","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.ejphar.2024.176907_bib56","first-page":"1","article-title":"Association of AGTR1 A1166C and CYP2C9\u22173 gene polymorphisms with the antihypertensive effect of valsartan","author":"Liu","year":"2022","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ejphar.2024.176907_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00168","article-title":"Pharmacogenomics of hypertension and preeclampsia: focus on gene\u2013gene interactions","volume":"9","author":"Luizon","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.ejphar.2024.176907_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/pgs-2018-0098","article-title":"Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions","volume":"19","author":"Luizon","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/pgs.13.173","article-title":"Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment","volume":"15","author":"Luo","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FPC.0000000000000050","article-title":"Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension","volume":"24","author":"Luo","year":"2014","journal-title":"Pharmacogenetics Genom."},{"issue":"9","key":"10.1016\/j.ejphar.2024.176907_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/FPC.0b013e328348c6db","article-title":"Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough","volume":"21","author":"Mas","year":"2011","journal-title":"Pharmacogenetics Genom."},{"issue":"8","key":"10.1016\/j.ejphar.2024.176907_bib62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/genes13081394","article-title":"Single nucleotide polymorphisms in amlodipine-associated genes and their correlation with blood pressure control among South African adults with hypertension","volume":"13","author":"Masilela","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2024.176907_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.niox.2012.10.002","article-title":"Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects","volume":"28","author":"Metzger","year":"2013","journal-title":"Nitric Oxide"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jch.12104","article-title":"Association of <scp>B<\/scp> 2 receptor polymorphisms and <scp>ACE<\/scp> activity with <scp>ACE<\/scp> inhibitor\u2013induced angioedema in black and mixed\u2010race South Africans","volume":"15","author":"Moholisa","year":"2013","journal-title":"J. Clin. Hypertens."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11906-014-0431-2","article-title":"Angiotensin II and vascular injury","volume":"16","author":"Montezano","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/tpj.2015.51","article-title":"A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough","volume":"16","author":"Mosley","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/pgs-2018-0157","article-title":"Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis","volume":"20","author":"Mu","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.HYP.36.1.127","article-title":"Bradykinin B 2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor\u2013related cough","volume":"36","author":"Mukae","year":"2000","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12872-020-01464-7","article-title":"Genetic forms and pathophysiology of essential arterial hypertension in minor indigenous peoples of Russia","volume":"20","author":"Mulerova","year":"2020","journal-title":"BMC Cardiovasc. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib70","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cvr\/cvp123","article-title":"ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload","volume":"83","author":"M\u00fcller","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002688","article-title":"Individualized angiotensin\u2010converting enzyme (ACE)\u2010Inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: the PERindopril GENEtic (PERGENE) risk model","volume":"5","author":"Oemrawsingh","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.ejphar.2024.176907_bib72","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00228-015-1872-5","article-title":"Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril","volume":"71","author":"Oliveira-Paula","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176907_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.niox.2016.03.006","article-title":"Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension","volume":"55\u201356","author":"Oliveira-Paula","year":"2016","journal-title":"Nitric Oxide"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12682","article-title":"Gene\u2013gene interactions among PRKCA , NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril","volume":"120","author":"Oliveira\u2010Paula","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib75","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1152\/physrev.00035.2016","article-title":"Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans","volume":"97","author":"Padmanabhan","year":"2017","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.ejphar.2024.176907_bib76","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib77","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/FTD.0000000000000255","article-title":"Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs","volume":"38","author":"Picard","year":"2016","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1614312","article-title":"The angiotensin-converting enzyme gene insertion\/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease","volume":"94","author":"Potaczek","year":"2005","journal-title":"Thrombosis and haemostasis"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib79","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4103\/ijp.IJP_593_19","article-title":"Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension","volume":"53","author":"Rahman","year":"2021","journal-title":"Indian J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib80","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/pgs-2016-0204","article-title":"Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses","volume":"18","author":"Rimpel\u00e4","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jval.2016.08.727","article-title":"Lessons learned when introducing pharmacogenomic panel testing into clinical practice","volume":"20","author":"Rosenman","year":"2017","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292402","article-title":"ACE I\/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: results from the LACE trial","volume":"18","author":"Rossios","year":"2023","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.ejphar.2024.176907_bib83","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib84","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00439-014-1476-7","article-title":"Missing heritability of common diseases and treatments outside the protein-coding exome","volume":"133","author":"Sadee","year":"2014","journal-title":"Hum. Genet."},{"issue":"12","key":"10.1016\/j.ejphar.2024.176907_bib85","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/00004872-199612000-00003","article-title":"Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies","volume":"14","author":"Sasaki","year":"1996","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.tpj.6500493","article-title":"Interaction between polymorphisms in the renin\u2013angiotensin\u2013system and angiotensin-converting enzyme inhibitor or \u03b2-blocker use and the risk of myocardial infarction and stroke","volume":"8","author":"Schelleman","year":"2008","journal-title":"Pharmacogenomics J."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib87","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjhyper.2004.11.032","article-title":"Mechanisms for the clinical benefits of angiotensin II receptor blockers","volume":"18","author":"Schmieder","year":"2005","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/jpm11060480","article-title":"Multi-institutional implementation of clinical decision support for APOL1, NAT2, and YEATS4 genotyping in antihypertensive management","volume":"11","author":"Schneider","year":"2021","journal-title":"J. Personalized Med."},{"issue":"7","key":"10.1016\/j.ejphar.2024.176907_bib89","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2174\/1573409916666201023113709","article-title":"In silico approach for exploring the role of AT1R polymorphism on its function, structure and drug interactions","volume":"17","author":"Sharma","year":"2021","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"11","key":"10.1016\/j.ejphar.2024.176907_bib90","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12272-020-01294-3","article-title":"ABCB1 c.2677G>T\/c.3435C>T diplotype increases the early-phase oral absorption of losartan","volume":"43","author":"Shin","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00228-012-1326-2","article-title":"eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril","volume":"69","author":"Silva","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib92","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/CIRCULATIONAHA.106.642058","article-title":"Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor","volume":"115","author":"Su","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JRS-230006","article-title":"Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension","volume":"35","author":"Sychev","year":"2024","journal-title":"Int. J. Risk Saf. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib94","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib95","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","article-title":"Pharmacogenetic factors affecting \u03b2-blocker metabolism and response","volume":"16","author":"Thomas","year":"2020","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"8","key":"10.1016\/j.ejphar.2024.176907_bib96","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/hrt.2004.036897","article-title":"Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function","volume":"91","author":"Trevelyan","year":"2005","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib97","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/HYP.0b013e31825b30f8","article-title":"Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker","volume":"59","author":"Turner","year":"2012","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejphar.2024.176907_bib98","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00228-014-1751-5","article-title":"Role of ACE I\/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts","volume":"70","author":"Urhan K\u00fc\u00e7\u00fck","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176907_bib99","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jpeds.2020.03.064","article-title":"Variants in ADRB1 and CYP2C9: association with response to atenolol and losartan in marfan syndrome","volume":"222","author":"Van Driest","year":"2020","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/tpj.2015.42","article-title":"CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors","volume":"16","author":"Wang","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176907_bib101","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176907_bib102","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence\u2010based framework for evaluating pharmacogenomics knowledge for personalized medicine","volume":"110","author":"Whirl\u2010Carrillo","year":"2021","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176907_bib103","series-title":"9 Steps to Improve Data Quality in Healthcare in 2023","year":"2023"},{"issue":"33","key":"10.1016\/j.ejphar.2024.176907_bib104","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.ejphar.2024.176907_bib105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2710.2009.01028.x","article-title":"Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans","volume":"34","author":"Woo","year":"2009","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"22","key":"10.1016\/j.ejphar.2024.176907_bib106","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1161\/hc4601.099404","article-title":"Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury","volume":"104","author":"Wu","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2024.176907_bib107","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41416-022-02029-5","article-title":"Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis","volume":"128","author":"Wu","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176907_bib108","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.peptides.2011.09.015","article-title":"Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor","volume":"32","author":"Yang","year":"2011","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176907_bib109","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clpt.2006.02.007","article-title":"Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors","volume":"79","author":"YU","year":"2006","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176907_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2010.00112","article-title":"Pharmacogenetics \u2013 challenges and opportunities ahead","author":"Zanger","year":"2010","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176907_bib111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1399-0004.2002.610104.x","article-title":"A prospective evaluation of the angiotensin\u2010converting enzyme D\/I polymorphism and left ventricular remodeling in the \u201cHealing and Early Afterload Reducing Therapy\u201d Study","volume":"61","author":"Zee","year":"2002","journal-title":"Clin. Genet."},{"issue":"20","key":"10.1016\/j.ejphar.2024.176907_bib112","first-page":"2461","article-title":"E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients","volume":"122","author":"Zhang","year":"2009","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejphar.2024.176907_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00236","article-title":"Polytropic influence of TRIB3 rs2295490 genetic polymorphism on response to antihypertensive agents in patients with essential hypertension","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"10304","key":"10.1016\/j.ejphar.2024.176907_bib114","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992400596X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992400596X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:15:16Z","timestamp":1729858516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992400596X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":113,"alternative-id":["S001429992400596X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176907","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176907"}}